Shares are tanking today due to a missed goal in a mid-stage study. CNBC's Meg Tirrell reports. Also, home-grown Zika comes to the U.S. » Read More
Valeant's underlying assets are not fairly valued by the market and it is capable of making a turnaround, says Rodman & Renshaw's Raghuram Selvaraju.
The "Fast Money" traders weighed election risks for biotech after Obama officially endorsed Hillary Clinton.
Jennifer Lawrence will play Theranos CEO Elizabeth Holmes in a movie about the battered biotechnology company, The Verge reports.
The accused fraudster blocked reporters from his Twitter feed as he toyed with starring in a new satirical musical.
Charity-run funds to help patients pay co-payments face scrutiny by prosecutors and increased federal oversight, USA Today reported.
Amgen said Wednesday that it has seen positive results for the chronic-migraine prevention drug it has been developing with Novartis.
Valeant is attempting to restructure a deal with Walgreens after warning it is losing money on medicines, reported the Financial Times.
David Maris, Specialty Pharmaceutical Analyst at Wells Fargo Securities, discusses his call history on Valeant and his latest bearish view that "things can always get worse" with the stock.
Piper Jaffray's David Amsellem explains that Valeant's profit losses were mostly due to the significant pressures on key products' selling prices.
Hit by "significant disruption" from investigations, embattled drugmaker Valeant reported a $373.7 million net loss. USA Today reports.
The "FMHR" traders discuss the pharma and biotech trade after Valeant's earnings miss.
CNBC's Meg Tirrell looks at some pharma and biotech stocks that are making news today.
Shares of Alexion fell nearly 12 percent Monday after the pharmaceutical company said it missed its goal in a late-stage trial of the drug Solaris.
Bethany McLean, Vanity Fair, discusses her in-depth expose of the ongoing saga at the pharmaceutical company which is currently under investigation for massive price hikes on lifesaving drugs.
FedEx, Sarepta Therapeutics and Verizon Communications are making headlines this morning before the opening bell.
Sarepta Therapeutics said regulators have requested additional data from a study for its muscle-wasting treatment.
Valeant Pharmaceuticals reported a lower-than-expected quarterly profit and cut its full-year earnings and revenue forecast.
CNBC's Landon Dowdy takes a look at three things to watch when Valeant reports first quarter earnings this morning.
Pharma bad boy Martin Shkreli unloaded as he left the federal courthouse in Brooklyn Monday.
Allergan CEO Brent Saunders tells CNBC's "Squawk on the Street" why attention from famed activist investor Carl Icahn's is a stamp of approval.
Get the best of CNBC in your inbox